Translational approaches: From fatty liver to non-alcoholic steatohepatitis

World Journal of Gastroenterology

Volumn , Issue 27, 2014, Pages 9038-9049

  Rosso, Natalia ^a   Chavez Tapia, Norberto C ^a,b   Tiribelli, Claudio ^a,c   Bellentani, Stefano ^a,d  

^a Fondazione Italiana Fegato Liver Research Center   (Italy)

^b LIVER RESEARCH UNIT   (Mexico)

^c UNIVERSITY OF TRIESTE   (Italy)

^d AUSL Modena   (Italy)

Author keywords

Experimental model; Fatty liver; In vitro; Inflammation; Metabolic syndrome; Obesity

Indexed keywords

BILE ACID; CYTOKINE; FATTY ACID; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INTERLEUKIN 6; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRANSCRIPTION FACTOR FOXO; TUMOR NECROSIS FACTOR ALPHA; AUTACOID;

ADIPOSE TISSUE; ATHEROSCLEROSIS; BACTERIAL TRANSLOCATION; CARDIOVASCULAR DISEASE; CHOLESTEROL INTAKE; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; DISEASE COURSE; ENDOPLASMIC RETICULUM STRESS; EXPERIMENTAL MODEL; EXTRACELLULAR MATRIX; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; KUPFFER CELL; LIPID METABOLISM; LIPID STORAGE; LIVER CELL CARCINOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; STELLATE CELL; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; COMPLICATION; DISEASE MODEL; FATTY LIVER; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TRANSLATIONAL RESEARCH;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FATTY LIVER; HUMANS; INFLAMMATION MEDIATORS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84905390509     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i27.9038     Document Type: Review

References (132)

1. Sartorio A, Del Col A, Agosti F, Mazzilli G, Bellentani S, Tiribelli C, Bedogni G. Predictors of non-alcoholic fatty liver disease in obese children. Eur J Clin Nutr 2007; 61: 877-883 [PMID: 17151586 DOI: 10.1038/sj.ejcn.1602588]
2. Chen SH, He F, Zhou HL, Wu HR, Xia C, Li YM. Relationship between nonalcoholic fatty liver disease and metabolic syndrome. J Dig Dis 2011; 12: 125-130 [PMID: 21401898 DOI: 10.1111/j.1751-2980.2011.00487.x]
3. Caldwell SH, Ikura Y, Iezzoni JC, Liu Z. Has natural selection in human populations produced two types of metabolic syndrome (with and without fatty liver)? J Gastroenterol Hepatol 2007; 22 Suppl 1: S11-S19 [PMID: 17567458 DOI: 10.1111/j.1440-1746.2006.04639.x]
4. Bulum T, Kolariæ B, Duvnjak L, Duvnjak M. Nonalcoholic fatty liver disease markers are associated with insulin resistance in type 1 diabetes. Dig Dis Sci 2011; 56: 3655-3663 [PMID: 21735081 DOI: 10.1007/s10620-011-1807-7]
5. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923 [PMID: 12668987 DOI: 10.1053/jhep.2003.50161]
6. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Blendis L, Halpern Z, Oren R. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol 2007; 47: 711-717 [PMID: 17850914 DOI: 10.1016/j.jhep.2007.06.020]
7. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Zvibel I, Goldiner I, Blendis L, Halpern Z, Oren R. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatology 2008; 48: 1791-1798 [PMID: 18972405 DOI: 10.1002/hep.22525]
8. Centis E, Moscatiello S, Bugianesi E, Bellentani S, Fracanzani AL, Calugi S, Petta S, Dalle Grave R, Marchesini G. Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease. J Hepatol 2013; 58: 771-777 [PMID: 23201248 DOI: 10.1016/j.jhep.2012.11.031]
9. Scaglioni F, Marino M, Ciccia S, Procaccini A, Busacchi M, Loria P, Lonardo A, Malavolti M, Battistini NC, Pellegrini M, Carubbi F, Bellentani S. Short-term multidisciplinary nonpharmacological intervention is effective in reducing liver fat content assessed non-invasively in patients with nonalcoholic fatty liver disease (NAFLD). Clin Res Hepatol Gastroenterol 2013; 37: 353-358 [PMID: 23273500 DOI: 10.1016/j.clinre.2012.10.009]
10. Liu CJ. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. J Gastroenterol Hepatol 2012; 27: 1555-1560 [PMID: 22741595 DOI: 10.1111/j.1440-1746.2012.07222.x]
11. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-845 [PMID: 9547102]
12. Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des 2010; 16: 1941-1951 [PMID: 20370677]
13. Diehl AM, Li ZP, Lin HZ, Yang SQ. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 2005; 54: 303-306 [PMID: 15647199 DOI: 10.1136/gut.2003.024935]
14. Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006; 6: 1-28 [PMID: 16406828 DOI: 10.1016/j.mito.2005.10.004]
15. Bachar E, Ariav Y, Ketzinel-Gilad M, Cerasi E, Kaiser N, Leibowitz G. Glucose amplifies fatty acid-induced endoplasmic reticulum stress in pancreatic beta-cells via activation of mTORC1. PLoS One 2009; 4: e4954 [PMID: 19305497 DOI: 10.1371/journal.pone.0004954]
16. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52: 1836-1846 [PMID: 21038418 DOI: 10.1002/hep.24001]
17. Moschen AR, Kaser S, Tilg H. Non-alcoholic steatohepatitis: a microbiota-driven disease. Trends Endocrinol Metab 2013; 24: 537-545 [PMID: 23827477 DOI: 10.1016/j.tem.2013.05.009]
18. Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, Van Hylckama Vlieg JE, Bloks VW, Groen AK, Heilig HG, Zoetendal EG, Stroes ES, de Vos WM, Hoekstra JB, Nieuwdorp M. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143: 913-916.e7 [PMID: 22728514 DOI: 10.1053/j.gastro.2012.06.031]
19. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53: 1883-1894 [PMID: 21381068 DOI: 10.1002/hep.24283]
20. Montecucco F, Bertolotto M, Vuilleumier N, Franciosi U, Puddu A, Minetti S, Delrio A, Quercioli A, Bergamini E, Ottonello L, Pende A, Lenglet S, Pelli G, Mach F, Dallegri F, Viviani GL. Acipimox reduces circulating levels of insulin and associated neutrophilic inflammation in metabolic syndrome. Am J Physiol Endocrinol Metab 2011; 300: E681-E690 [PMID: 21266669 DOI: 10.1152/ajpendo.00527.2010]
21. Kim F, Pham M, Maloney E, Rizzo NO, Morton GJ, Wisse BE, Kirk EA, Chait A, Schwartz MW. Vascular inflammation, insulin resistance, and reduced nitric oxide production precede the onset of peripheral insulin resistance. Arterioscler Thromb Vasc Biol 2008; 28: 1982-1988 [PMID: 18772497 DOI: 10.1161/ATVBAHA.108.169722]
22. Gage MC, Yuldasheva NY, Viswambharan H, Sukumar P, Cubbon RM, Galloway S, Imrie H, Skromna A, Smith J, Jackson CL, Kearney MT, Wheatcroft SB. Endothelium-specific insulin resistance leads to accelerated atherosclerosis in areas with disturbed flow patterns: a role for reactive oxygen species. Atherosclerosis 2013; 230: 131-139 [PMID: 23958265 DOI: 10.1016/j.atherosclerosis.2013.06.017]
23. Tsuchiya K, Tanaka J, Shuiqing Y, Welch CL, DePinho RA, Tabas I, Tall AR, Goldberg IJ, Accili D. FoxOs integrate pleiotropic actions of insulin in vascular endothelium to protect mice from atherosclerosis. Cell Metab 2012; 15: 372-381 [PMID: 22405072 DOI: 10.1016/j.cmet.2012.01.018]
24. Davis RC, Castellani LW, Hosseini M, Ben-Zeev O, Mao HZ, Weinstein MM, Jung DY, Jun JY, Kim JK, Lusis AJ, Péterfy M. Early hepatic insulin resistance precedes the onset of diabetes in obese C57BLKS-db/db mice. Diabetes 2010; 59: 1616-1625 [PMID: 20393148 DOI: 10.2337/db09-0878]
25. Carbone F, Montecucco F, Mach F, Pontremoli R, Viazzi F. The liver and the kidney: two critical organs influencing the atherothrombotic risk in metabolic syndrome. Thromb Haemost 2013; 110: 940-958 [PMID: 23966104 DOI: 10.1160/TH13-06-0499]
26. Targher G, Chonchol M, Pichiri I, Zoppini G. Risk of cardiovascular disease and chronic kidney disease in diabetic patients with non-alcoholic fatty liver disease: just a coincidence? J Endocrinol Invest 2011; 34: 544-551 [PMID: 21427524 DOI: 10.3275/7614]
27. Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 2004; 15: 2792-2800 [PMID: 15504932 DOI: 10.1097/01.ASN.0000141966.69934.21]
28. Wolf G, Chen S, Han DC, Ziyadeh FN. Leptin and renal disease. Am J Kidney Dis 2002; 39: 1-11 [PMID: 11774095 DOI: 10.1053/ajkd.2002.29865]
29. Lonardo A, Bellentani S, Ratziu V, Loria P. Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies? Expert Rev Gastroenterol Hepatol 2011; 5: 279-289 [PMID: 21476922 DOI: 10.1586/egh.11.19]
30. Rask E, Olsson T, Söderberg S, Johnson O, Seckl J, Holst JJ, Ahrén B. Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care 2001; 24: 1640-1645 [PMID: 11522713]
31. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004; 287: E199-E206 [PMID: 15271645 DOI: 10.1152/ajpendo.00545.2003]
32. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46-52 [PMID: 3514343]
33. Gautier JF, Choukem SP, Girard J. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab 2008; 34 Suppl 2: S65-S72 [PMID: 18640588 DOI: 10.1016/S1262-3636(08)73397-4]
34. Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK, Anania FA. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010; 51: 1584-1592 [PMID: 20225248 DOI: 10.1002/hep.23569]
35. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exen-din- 4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006; 43: 173-181 [PMID: 16374859 DOI: 10.1002/hep.21006]
36. Trevaskis JL, Griffin PS, Wittmer C, Neuschwander-Tetri BA, Brunt EM, Dolman CS, Erickson MR, Napora J, Parkes DG, Roth JD. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol 2012; 302: G762-G772 [PMID: 22268099 DOI: 10.1152/ajpgi.00476.2011]
37. Ben-Shlomo S, Zvibel I, Shnell M, Shlomai A, Chepurko E, Halpern Z, Barzilai N, Oren R, Fishman S. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol 2011; 54: 1214-1223 [PMID: 21145820 DOI: 10.1016/j.jhep.2010.09.032]
38. Svegliati-Baroni G, Saccomanno S, Rychlicki C, Agostinelli L, De Minicis S, Candelaresi C, Faraci G, Pacetti D, Vivarelli M, Nicolini D, Garelli P, Casini A, Manco M, Mingrone G, Risaliti A, Frega GN, Benedetti A, Gastaldelli A. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int 2011; 31: 1285-1297 [PMID: 21745271 DOI: 10.1111/j.1478-3231.2011.02462.x]
39. Sharma S, Mells JE, Fu PP, Saxena NK, Anania FA. GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS One 2011; 6: e25269 [PMID: 21957486 DOI: 10.1371/journal.pone.0025269]
40. Staels B, Fonseca VA. Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration. Diabetes Care 2009; 32 Suppl 2: S237-S245 [PMID: 19875558 DOI: 10.2337/dc09-S355]
41. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009; 89: 147-191 [PMID: 19126757 DOI: 10.1152/physrev.00010.2008]
42. Andersén E, Karlaganis G, Sjövall J. Altered bile acid profiles in duodenal bile and urine in diabetic subjects. Eur J Clin Invest 1988; 18: 166-172 [PMID: 3133222]
43. Knop FK. Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes? Am J Physiol Endocrinol Metab 2010; 299: E10-E13 [PMID: 20424139 DOI: 10.1152/ajpendo.00137.2010]
44. Laplante M, Sabatini DM. mTORC1 activates SREBP-1c and uncouples lipogenesis from gluconeogenesis. Proc Natl Acad Sci USA 2010; 107: 3281-3282 [PMID: 20167806 DOI: 10.1073/pnas.1000323107]
45. Blaslov K, Zibar K, Bulum T, Duvnjak L. Effect of exenatide therapy on hepatic fat quantity and hepatic biomarkers in type 2 diabetic patients. Clin Res Hepatol Gastroenterol 2013; Epub ahead of print [PMID: 24315013 DOI: 10.1016/j.clinre.2013.10.013]
46. Holst JJ, Vilsbøll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009; 297: 127-136 [PMID: 18786605 DOI: 10.1016/j.mce.2008.08.012]
47. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, Dillon P, Pruzanski M, Shapiro D. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 574-582.e1 [PMID: 23727264 DOI: 10.1053/j.gastro.2013.05.042]
48. Tanaka S, Wands JR. Insulin receptor substrate 1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor beta1-induced apoptosis. Cancer Res 1996; 56: 3391-3394 [PMID: 8758899]
49. Ish-Shalom D, Christoffersen CT, Vorwerk P, Sacerdoti-Sierra N, Shymko RM, Naor D, De Meyts P. Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor. Diabetologia 1997; 40 Suppl 2: S25-S31 [PMID: 9248698]
50. Page JM, Harrison SA. NASH and HCC. Clin Liver Dis 2009; 13: 631-647 [PMID: 19818310 DOI: 10.1016/j.cld.2009.07.007]
51. Stickel F, Hellerbrand C. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut 2010; 59: 1303-1307 [PMID: 20650925 DOI: 10.1136/gut.2009.199661]
52. Yu J, Shen J, Sun TT, Zhang X, Wong N. Obesity, insulin resistance, NASH and hepatocellular carcinoma. Semin Cancer Biol 2013; 23: 483-491 [PMID: 23876851 DOI: 10.1016/j.semcancer.2013.07.003]
53. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011; 332: 1519-1523 [PMID: 21700865 DOI: 10.1126/science.1204265]
54. Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, Bhanot S, Monia BP, Li YX, Diehl AM. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007; 45: 1366-1374 [PMID: 17476695 DOI: 10.1002/hep.21655]
55. Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 2008; 28: 360-369 [PMID: 18956292 DOI: 10.1055/s-0028-1091980]
56. Bass NM. Lipidomic dissection of nonalcoholic steatohepatitis: moving beyond foie gras to fat traffic. Hepatology 2010; 51: 4-7 [PMID: 20034031 DOI: 10.1002/hep.23458]
57. Choi SS, Diehl AM. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. Curr Opin Lipidol 2008; 19: 295-300 [PMID: 18460922 DOI: 10.1097/MOL.0b013e3282ff5e55]
58. Bikman BT, Summers SA. Ceramides as modulators of cellular and whole-body metabolism. J Clin Invest 2011; 121: 4222-4230 [PMID: 22045572 DOI: 10.1172/JCI57144]
59. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010; 52: 774-788 [PMID: 20683968 DOI: 10.1002/hep.23719]
60. Tanti JF, Jager J. Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. Curr Opin Pharmacol 2009; 9: 753-762 [PMID: 19683471 DOI: 10.1016/j.coph.2009.07.004]
61. Wouters K, van Bilsen M, van Gorp PJ, Bieghs V, Lütjohann D, Kerksiek A, Staels B, Hofker MH, Shiri-Sverdlov R. Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice. FEBS Lett 2010; 584: 1001-1005 [PMID: 20114046 DOI: 10.1016/j.febslet.2010.01.046]
62. Zhao L, Chen Y, Tang R, Chen Y, Li Q, Gong J, Huang A, Varghese Z, Moorhead JF, Ruan XZ. Inflammatory stress exacerbates hepatic cholesterol accumulation via increasing cholesterol uptake and de novo synthesis. J Gastroenterol Hepatol 2011; 26: 875-883 [PMID: 21488946 DOI: 10.1111/j.1440-1746.2010.06560.x]
63. Li L, Hossain MA, Sadat S, Hager L, Liu L, Tam L, Schroer S, Huogen L, Fantus IG, Connelly PW, Woo M, Ng DS. Lecithin cholesterol acyltransferase null mice are protected from diet-induced obesity and insulin resistance in a genderspecific manner through multiple pathways. J Biol Chem 2011; 286: 17809-17820 [PMID: 21454561 DOI: 10.1074/jbc.M110.180893]
64. Hager L, Li L, Pun H, Liu L, Hossain MA, Maguire GF, Naples M, Baker C, Magomedova L, Tam J, Adeli K, Cummins CL, Connelly PW, Ng DS. Lecithin: cholesterol acyltransferase deficiency protects against cholesterol-induced hepatic endoplasmic reticulum stress in mice. J Biol Chem 2012; 287: 20755-20768 [PMID: 22500017 DOI: 10.1074/jbc.M112.340919]
65. Bernardi P. Mitochondrial transport of cations: channels, exchangers, and permeability transition. Physiol Rev 1999; 79: 1127-1155 [PMID: 10508231]
66. Scorrano L, Oakes SA, Opferman JT, Cheng EH, Sorcinelli MD, Pozzan T, Korsmeyer SJ. BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis. Science 2003; 300: 135-139 [PMID: 12624178 DOI: 10.1126/science.1081208]
67. Musso G, Cassader M, Bo S, De Michieli F, Gambino R. Sterol regulatory element-binding factor 2 (SREBF-2) predicts 7-year NAFLD incidence and severity of liver disease and lipoprotein and glucose dysmetabolism. Diabetes 2013; 62: 1109-1120 [PMID: 23274901 DOI: 10.2337/db12-0858]
68. Musso G, Gambino R, Cassader M. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog Lipid Res 2013; 52: 175-191 [PMID: 23206728 DOI: 10.1016/j.plipres.2012.11.002]
69. Yasutake K, Nakamuta M, Shima Y, Ohyama A, Masuda K, Haruta N, Fujino T, Aoyagi Y, Fukuizumi K, Yoshimoto T, Takemoto R, Miyahara T, Harada N, Hayata F, Nakashima M, Enjoji M. Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol. Scand J Gastroenterol 2009; 44: 471-477 [PMID: 19058085 DOI: 10.1080/00365520802588133]
70. Asrih M, Jornayvaz FR. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. J Endocrinol 2013; 218: R25-R36 [PMID: 23833274 DOI: 10.1530/JOE-13-0201]
71. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009; 50: 957-969 [PMID: 19585655 DOI: 10.1002/hep.23046]
72. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000; 343: 1467-1476 [PMID: 11078773 DOI: 10.1056/NEJM200011163432007]
73. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808 [PMID: 14679176 DOI: 10.1172/JCI19246]
74. Kunt T, Forst T, Früh B, Flohr T, Schneider S, Harzer O, Pfützner A, Engelbach M, Löbig M, Beyer J. Binding of monocytes from normolipidemic hyperglycemic patients with type 1 diabetes to endothelial cells is increased in vitro. Exp Clin Endocrinol Diabetes 1999; 107: 252-256 [PMID: 10433064 DOI: 10.1055/s-0029-1212108]
75. Bulum T, KolariÄ B, Duvnjak L. Decreased serum monocytes and elevated neutrophils as additional markers of insulin resistance in type 1 diabetes. Int J Diabetes Dev Ctries 2013; 1-6 [DOI: 10.1007/s13410-013-0176-5]
76. Bunn RC, Cockrell GE, Ou Y, Thrailkill KM, Lumpkin CK, Fowlkes JL. Palmitate and insulin synergistically induce IL-6 expression in human monocytes. Cardiovasc Diabetol 2010; 9: 73 [PMID: 21054880 DOI: 10.1186/1475-2840-9-73]
77. Chavez-Tapia NC, Rosso N, Tiribelli C. Effect of intracellular lipid accumulation in a new model of non-alcoholic fatty liver disease. BMC Gastroenterol 2012; 12: 20 [PMID: 22380754 DOI: 10.1186/1471-230X-12-20]
78. Joshi-Barve S, Barve SS, Amancherla K, Gobejishvili L, Hill D, Cave M, Hote P, McClain CJ. Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes. Hepatology 2007; 46: 823-830 [PMID: 17680645 DOI: 10.1002/hep.21752]
79. Chávez-Tapia NC, Rosso N, Uribe M, Bojalil R, Tiribelli C. Kinetics of the inflammatory response induced by free fatty acid accumulation in hepatocytes. Ann Hepatol 2013; 13: 113-120 [PMID: 24378274]
80. Bra˚kenhielm E, Veitonmäki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, Funahashi T, Cao Y. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA 2004; 101: 2476-2481 [PMID: 14983034]
81. Kamada Y, Matsumoto H, Tamura S, Fukushima J, Kiso S, Fukui K, Igura T, Maeda N, Kihara S, Funahashi T, Matsuzawa Y, Shimomura I, Hayashi N. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J Hepatol 2007; 47: 556-564 [PMID: 17459514 DOI: 10.1016/j.jhep.2007.03.020]
82. Braunersreuther V, Viviani GL, Mach F, Montecucco F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol 2012; 18: 727-735 [PMID: 22371632 DOI: 10.3748/wjg.v18.i8.727]
83. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-1192 [PMID: 11266382 DOI: 10.1053/gast.2001.23256]
84. Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 1999; 282: 1659-1664 [PMID: 10553793]
85. Serviddio G, Sastre J, Bellanti F, Viña J, Vendemiale G, Altomare E. Mitochondrial involvement in non-alcoholic steatohepatitis. Mol Aspects Med 2008; 29: 22-35 [PMID: 18061659 DOI: 10.1016/j.mam.2007.09.014]
86. Teodoro JS, Rolo AP, Duarte FV, Simões AM, Palmeira CM. Differential alterations in mitochondrial function induced by a choline-deficient diet: understanding fatty liver disease progression. Mitochondrion 2008; 8: 367-376 [PMID: 18765303 DOI: 10.1016/j.mito.2008.07.008]
87. Leamy AK, Egnatchik RA, Young JD. Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. Prog Lipid Res 2013; 52: 165-174 [PMID: 23178552 DOI: 10.1016/j.plipres.2012.10.004]
88. Sunny NE, Parks EJ, Browning JD, Burgess SC. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab 2011; 14: 804-810 [PMID: 22152305 DOI: 10.1016/j.cmet.2011.11.004]
89. Satapati S, Sunny NE, Kucejova B, Fu X, He TT, Méndez-Lucas A, Shelton JM, Perales JC, Browning JD, Burgess SC. Elevated TCA cycle function in the pathology of diet-induced hepatic insulin resistance and fatty liver. J Lipid Res 2012; 53: 1080-1092 [PMID: 22493093 DOI: 10.1194/jlr.M023382]
90. Borradaile NM, Han X, Harp JD, Gale SE, Ory DS, Schaffer JE. Disruption of endoplasmic reticulum structure and integrity in lipotoxic cell death. J Lipid Res 2006; 47: 2726-2737 [PMID: 16960261 DOI: 10.1194/jlr.M600299-JLR200]
91. Hickson-Bick DL, Sparagna GC, Buja LM, McMillin JB. Palmitate-induced apoptosis in neonatal cardiomyocytes is not dependent on the generation of ROS. Am J Physiol Heart Circ Physiol 2002; 282: H656-H664 [PMID: 11788415 DOI: 10.1152/ajpheart.00726.2001]
92. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88: 125-172 [PMID: 18195085 DOI: 10.1152/physrev.00013.2007]
93. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-1669 [PMID: 18471545 DOI: 10.1053/j.gastro.2008.03.003]
94. Gressner OA, Weiskirchen R, Gressner AM. Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options. Comp Hepatol 2007; 6: 7 [PMID: 17663771 DOI: 10.1186/1476-5926-6-7]
95. Dooley S, Delvoux B, Streckert M, Bonzel L, Stopa M, ten Dijke P, Gressner AM. Transforming growth factor beta signal transduction in hepatic stellate cells via Smad2/3 phosphorylation, a pathway that is abrogated during in vitro progression to myofibroblasts. TGFbeta signal transduction during transdifferentiation of hepatic stellate cells. FEBS Lett 2001; 502: 4-10 [PMID: 11478938]
96. Cavin LG, Romieu-Mourez R, Panta GR, Sun J, Factor VM, Thorgeirsson SS, Sonenshein GE, Arsura M. Inhibition of CK2 activity by TGF-beta1 promotes IkappaB-alpha protein stabilization and apoptosis of immortalized hepatocytes. Hepatology 2003; 38: 1540-1551 [PMID: 14647065 DOI: 10.1016/j.hep.2003.09.019]
97. Proell V, Carmona-Cuenca I, Murillo MM, Huber H, Fabregat I, Mikulits W. TGF-beta dependent regulation of oxygen radicals during transdifferentiation of activated hepatic stellate cells to myofibroblastoid cells. Comp Hepatol 2007; 6: 1 [PMID: 17311678 DOI: 10.1186/1476-5926-6-1]
98. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-438 [PMID: 7382552]
99. Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 2006; 87: 1-16 [PMID: 16436109 DOI: 10.1111/j.0959-9673.2006.00465.x]
100. Koteish A, Mae Diehl A. Animal models of steatohepatitis. Best Pract Res Clin Gastroenterol 2002; 16: 679-690 [PMID: 12406439]
101. Larter CZ, Yeh MM. Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol 2008; 23: 1635-1648 [PMID: 18752564 DOI: 10.1111/j.1440-1746.2008.05543.x]
102. Takahashi Y, Soejima Y, Fukusato T. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2012; 18: 2300-2308 [PMID: 22654421 DOI: 10.3748/wjg.v18.i19.2300]
103. Rinella ME, Green RM. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol 2004; 40: 47-51 [PMID: 14672613]
104. Schattenberg JM, Wang Y, Singh R, Rigoli RM, Czaja MJ. Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling. J Biol Chem 2005; 280: 9887-9894 [PMID: 15632182 DOI: 10.1074/jbc.M410310200]
105. Martínez-Chantar ML, Corrales FJ, Martínez-Cruz LA, García-Trevijano ER, Huang ZZ, Chen L, Kanel G, Avila MA, Mato JM, Lu SC. Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A. FASEB J 2002; 16: 1292-1294 [PMID: 12060674 DOI: 10.1096/fj.02-0078fje]
106. Nakayama H, Otabe S, Ueno T, Hirota N, Yuan X, Fukutani T, Hashinaga T, Wada N, Yamada K. Transgenic mice expressing nuclear sterol regulatory element-binding protein 1c in adipose tissue exhibit liver histology similar to nonalcoholic steatohepatitis. Metabolism 2007; 56: 470-475 [PMID: 17379003 DOI: 10.1016/j.metabol.2006.11.004]
107. Schattenberg JM, Galle PR. Animal models of non-alcoholic steatohepatitis: of mice and man. Dig Dis 2010; 28: 247-254 [PMID: 20460919 DOI: 10.1159/000282097]
108. Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 2008; 295: G987-G995 [PMID: 18772365 DOI: 10.1152/ajpgi.90272.2008]
109. Kawasaki T, Igarashi K, Koeda T, Sugimoto K, Nakagawa K, Hayashi S, Yamaji R, Inui H, Fukusato T, Yamanouchi T. Rats fed fructose-enriched diets have characteristics of nonalcoholic hepatic steatosis. J Nutr 2009; 139: 2067-2071 [PMID: 19776184]
110. Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q, Ren C, Ponomarenko A, DeCarli LM. Model of nonalcoholic steatohepatitis. Am J Clin Nutr 2004; 79: 502-509 [PMID: 14985228]
111. Ferramosca A, Conte A, Damiano F, Siculella L, Zara V. Differential effects of high-carbohydrate and high-fat diets on hepatic lipogenesis in rats. Eur J Nutr 2014; 53: 1103-1114 [PMID: 24197180 DOI: 10.1007/s00394-013-0613-8]
112. Matsuzawa N, Takamura T, Kurita S, Misu H, Ota T, Ando H, Yokoyama M, Honda M, Zen Y, Nakanuma Y, Miyamoto K, Kaneko S. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 2007; 46: 1392-1403 [PMID: 17929294 DOI: 10.1002/hep.21874]
113. Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, Magnuson MA, Kahn CR. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 2000; 6: 87-97 [PMID: 10949030]
114. Cohen SE, Kokkotou E, Biddinger SB, Kondo T, Gebhardt R, Kratzsch J, Mantzoros CS, Kahn CR. High circulating leptin receptors with normal leptin sensitivity in liver-specific insulin receptor knock-out (LIRKO) mice. J Biol Chem 2007; 282: 23672-23678 [PMID: 17556363 DOI: 10.1074/jbc.M704053200]
115. Kohli R, Kirby M, Xanthakos SA, Softic S, Feldstein AE, Saxena V, Tang PH, Miles L, Miles MV, Balistreri WF, Woods SC, Seeley RJ. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 2010; 52: 934-944 [PMID: 20607689 DOI: 10.1002/hep.23797]
116. Ito M, Suzuki J, Tsujioka S, Sasaki M, Gomori A, Shirakura T, Hirose H, Ito M, Ishihara A, Iwaasa H, Kanatani A. Longitudinal analysis of murine steatohepatitis model induced by chronic exposure to high-fat diet. Hepatol Res 2007; 37: 50-57 [PMID: 17300698 DOI: 10.1111/j.1872-034X.2007.00008.x]
117. Romestaing C, Piquet MA, Bedu E, Rouleau V, Dautresme M, Hourmand-Ollivier I, Filippi C, Duchamp C, Sibille B. Long term highly saturated fat diet does not induce NASH in Wistar rats. Nutr Metab (Lond) 2007; 4: 4 [PMID: 17313679 DOI: 10.1186/1743-7075-4-4]
118. Yilmaz Y. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment Pharmacol Ther 2012; 36: 815-823 [PMID: 22966992 DOI: 10.1111/apt.12046]
119. Lonardo A, Loria P, Argo C, Caldwell S. Perspectives on cellular dysfunction in nonalcoholic steatohepatitis: a case of 'multiorganelle failure'? Proceedings of a virtual workshop on nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol 2011; 5: 135-139 [PMID: 21476906 DOI: 10.1586/egh.11.24]
120. Arrese M. Burning hepatic fat: therapeutic potential for liver-specific thyromimetics in the treatment of nonalcoholic fatty liver disease. Hepatology 2009; 49: 348-351 [PMID: 19177580 DOI: 10.1002/hep.22783]
121. Chavez-Tapia NC, Rosso N, Tiribelli C. In vitro models for the study of non-alcoholic fatty liver disease. Curr Med Chem 2011; 18: 1079-1084 [PMID: 21254970]
122. Malhi H, Bronk SF, Werneburg NW, Gores GJ. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem 2006; 281: 12093-12101 [PMID: 16505490 DOI: 10.1074/jbc.M510660200]
123. Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, Pettinelli P, Poniachik J. Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 2004; 106: 635-643 [PMID: 14720121 DOI: 10.1042/CS20030326]
124. Gómez-Lechón MJ, Donato MT, Martínez-Romero A, Jiménez N, Castell JV, O'Connor JE. A human hepatocellular in vitro model to investigate steatosis. Chem Biol Interact 2007; 165: 106-116 [PMID: 17188672 DOI: 10.1016/j.cbi.2006.11.004]
125. Ricchi M, Odoardi MR, Carulli L, Anzivino C, Ballestri S, Pinetti A, Fantoni LI, Marra F, Bertolotti M, Banni S, Lonardo A, Carulli N, Loria P. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J Gastroenterol Hepatol 2009; 24: 830-840 [PMID: 19207680 DOI: 10.1111/j.1440-1746.2008.05733.x]
126. Listenberger LL, Ory DS, Schaffer JE. Palmitate-induced apoptosis can occur through a ceramide-independent pathway. J Biol Chem 2001; 276: 14890-14895 [PMID: 11278654 DOI: 10.1074/jbc.M010286200]
127. Krause P, Saghatolislam F, Koenig S, Unthan-Fechner K, Probst I. Maintaining hepatocyte differentiation in vitro through co-culture with hepatic stellate cells. In Vitro Cell Dev Biol Anim 2009; 45: 205-212 [PMID: 19184253 DOI: 10.1007/s11626-008-9166-1]
128. Pradere JP, Kluwe J, De Minicis S, Jiao JJ, Gwak GY, Dapito DH, Jang MK, Guenther ND, Mederacke I, Friedman R, Dragomir AC, Aloman C, Schwabe RF. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. Hepatology 2013; 58: 1461-1473 [PMID: 23553591 DOI: 10.1002/hep.26429]
129. Coulouarn C, Corlu A, Glaise D, Guénon I, Thorgeirsson SS, Clément B. Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Res 2012; 72: 2533-2542 [PMID: 22419664 DOI: 10.1158/0008-5472.CAN-11-3317]
130. Kim WR, Brown RS, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002; 36: 227-242 [PMID: 12085369 DOI: 10.1053/jhep.2002.34734]
131. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013; 58: 593-608 [PMID: 23419824 DOI: 10.1016/j.jhep.2012.12.005]
132. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010; 28: 155-161 [PMID: 20460905 DOI: 10.1159/000282080]